Evidence map›Paper›PMID 32914391›Full record

ArticleMolecular imaging and biology2021

A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics.

Lin Qiu, Qingyu Lin, Zhan Si, Hui Tan, Guobing Liu, Jun Zhou, Tingting Wang, Yue Chen, Yingzhao Huang, Tao Yu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Lin QiuDepartment of Nuclear Medicine, Zhongshan Hospital Fudan University, No. 180, Fenglin Road, Xuhui District, Shanghai, 200032, China.
Qingyu LinDepartment of Nuclear Medicine, Zhongshan Hospital Fudan University, No. 180, Fenglin Road, Xuhui District, Shanghai, 200032, China.
Zhan SiDepartment of Nuclear Medicine, Zhongshan Hospital Fudan University, No. 180, Fenglin Road, Xuhui District, Shanghai, 200032, China.
Hui TanDepartment of Nuclear Medicine, Zhongshan Hospital Fudan University, No. 180, Fenglin Road, Xuhui District, Shanghai, 200032, China.
Guobing LiuDepartment of Nuclear Medicine, Zhongshan Hospital Fudan University, No. 180, Fenglin Road, Xuhui District, Shanghai, 200032, China.
Jun ZhouDepartment of Nuclear Medicine, Zhongshan Hospital Fudan University, No. 180, Fenglin Road, Xuhui District, Shanghai, 200032, China.
Tingting WangDepartment of Nuclear Medicine, Zhongshan Hospital Fudan University, No. 180, Fenglin Road, Xuhui District, Shanghai, 200032, China.
Yue ChenDepartment of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Yingzhao HuangWuXi AppTec, Shanghai, China.
Tao YuWuXi AppTec, Shanghai, China.
Mingzhi JinWuXi Biologics (Shanghai) Co., Ltd, Shanghai, China.
Dengfeng ChengDepartment of Nuclear Medicine, Zhongshan Hospital Fudan University, No. 180, Fenglin Road, Xuhui District, Shanghai, 200032, China. cheng.dengfeng@zs-hospital.sh.cn.
Hongcheng ShiDepartment of Nuclear Medicine, Zhongshan Hospital Fudan University, No. 180, Fenglin Road, Xuhui District, Shanghai, 200032, China. shihongcheng163@163.com.ORCID 0000-0003-1922-1359
Fudan University · CNWuXi AppTec (China) · CNAffiliated Hospital of Southwest Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePreviously, we successfully developed a pretargeted imaging strategy (atezolizumab-TCO/[ PROCEDURES: Pretargeted molecular probes [

results[

conclusionOur novel pretargeted imaging strategy (cetuximab-TCO/[

Indexed as

Molecular ImagingAnimalsCetuximabColorectal NeoplasmsErbB ReceptorsHCT116 CellsHumansLigandsMiceMolecular ProbesOrganotechnetium CompoundsPeptidesRadiopharmaceuticalsTissue DistributionCetuximabErbB ReceptorsLigandsMolecular ProbesOrganotechnetium CompoundsPeptidesRadiopharmaceuticalsCetuximabClick chemistryColorectal cancerEGFRPretargeted imaging

Identifiers

PMID32914391
OpenAlexW3085699019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.